about
Melanoma: oncogenic drivers and the immune systemPathways and therapeutic targets in melanomaA RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressorBeyond BRAF: where next for melanoma therapy?CIViC databaseRaf-interactome in tuning the complexity and diversity of Raf function.Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.Negative feedback regulation of the ERK1/2 MAPK pathwayCooperation between Noncanonical Ras Network Mutations.Resistance to Raf inhibition in cancer.The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.Molecular pathways and therapeutic targets in lung cancerIdentification of PLX4032-resistance mechanisms and implications for novel RAF inhibitorsThe NF1 somatic mutational landscape in sporadic human cancers.Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.Understanding the biology of melanoma and therapeutic implicationsMAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.Melanoma: clinical features and genomic insights.The MAPK pathway as an apoptosis enhancer in melanoma.A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.The NF1 gene revisited - from bench to bedside.The MAPK pathway across different malignancies: a new perspective.Genotyping of cutaneous melanoma.BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Genomic Classification of Cutaneous MelanomaOvercoming resistance to BRAF inhibition in BRAF-mutated metastatic melanomaMelanoma genotypes and phenotypes get personal.Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations?Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.Resistance to BRAF inhibitors induces glutamine dependency in melanoma cellsAn unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance.Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation.NF1 Mutations Are Common in Desmoplastic Melanoma.The RasGAP gene, RASAL2, is a tumor and metastasis suppressorIdentifying the Ubiquitin Ligase complex that regulates the NF1 tumor suppressor and Ras.Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma.
P2860
Q26775598-6F656C35-9E05-4DBC-BF17-CAF82BC69660Q26865736-3806096E-75D6-47DE-8926-336F4FBC236FQ27003534-64587CDF-8A6A-4910-878E-D8E068210781Q27006853-B4766DE5-C026-4666-B386-3EAB51C3A311Q27612411-8B61A0BA-FB91-4573-91C2-F39C82F26A66Q27692653-8A4ADCCB-7EDD-4B37-8606-B222B05F7B4AQ27852894-85B299B7-F9B3-4032-BC5C-E7BF2AD662BBQ28079202-B8D2D0E7-CB4B-4804-A54D-89F916DB492EQ30300930-7EB7AEB3-46C2-4906-AAB3-2763C2DB8C79Q33651779-41813894-1C72-4722-A9FA-83ED71F6A204Q33683959-71CA8CFC-87FD-403A-AEDB-51A8B68F11DFQ33688872-42997A99-2E63-49BC-96AD-A6DD82137F18Q33784436-99FB763A-B1CF-42C3-868D-DEEDAF73338EQ33823452-1DBF8EAF-D742-4394-8E3D-51BBEE72C2ECQ33917547-5290168D-318F-4FBB-81CF-5C877045A0B5Q33978378-A22CB2AD-F430-4AE9-A18A-0D755BDDCF72Q34022861-2BF799EF-D0F8-45FC-A7EA-41469D9FF571Q34083191-A3D32D77-4F67-4EFA-A57A-F493C125C9A2Q34104135-C7751129-EAD7-44F8-9D82-78B10DC0F8D6Q34132936-BCC47B47-238A-4795-9E75-23CB2A76437AQ34227509-6494EAE7-B25C-4048-B311-DDEE73CAADD4Q34459097-2D7B768B-EBDF-4536-B176-D375E74983E4Q34667738-1160413E-6C60-4B32-9316-67A1916B3953Q34667825-E6E0FEB7-416E-4404-9BF9-36ADC5EBC539Q34670776-DB4CD2AF-D02F-41B7-B2F8-6440FC879D6FQ34786402-38542817-3E11-4637-8029-03C556A553A3Q34788817-E8842DCC-E5AA-4618-934A-842014E8F725Q35337927-D9C9E315-B942-4990-A0E0-1876BC60289DQ35477813-604B3FF7-5C1F-4688-8589-3C1979C38A44Q35657827-4573C4A3-9E59-415A-B5EB-A6F5C649F270Q35987649-58C16374-389F-446B-9E19-3D85977A10EFQ36232159-78C972B0-C16A-42B0-A201-97CE866D5242Q36476849-C5A0B643-AD60-4205-8C76-1F35EA16174FQ36677236-75EC94F4-446C-4923-AE8C-AC06C0ABDB31Q37269164-648526C0-18CA-45AB-A16E-A3167D21570DQ37286915-E9519A13-B620-4E68-908C-406CBF0004DEQ37293348-ACEC3C6E-DCA9-4D95-8E6E-8B7210B15ED3Q37435516-109D3A5F-F064-4D38-B1C8-5609B1979717Q37623870-1A838FCF-02E7-4B7E-B0DF-F22FA60D497DQ37705251-7C2694D6-2AB2-4499-B484-613816BD173B
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Elucidating distinct roles for NF1 in melanomagenesis
@ast
Elucidating distinct roles for NF1 in melanomagenesis
@en
Elucidating distinct roles for NF1 in melanomagenesis.
@nl
type
label
Elucidating distinct roles for NF1 in melanomagenesis
@ast
Elucidating distinct roles for NF1 in melanomagenesis
@en
Elucidating distinct roles for NF1 in melanomagenesis.
@nl
altLabel
Elucidating Distinct Roles for NF1 in Melanomagenesis
@en
prefLabel
Elucidating distinct roles for NF1 in melanomagenesis
@ast
Elucidating distinct roles for NF1 in melanomagenesis
@en
Elucidating distinct roles for NF1 in melanomagenesis.
@nl
P2093
P2860
P50
P3181
P1433
P1476
Elucidating distinct roles for NF1 in melanomagenesis
@en
P2093
Bryan Johnson
Dennie T Frederick
Jennifer A Wargo
Karen Cichowski
Ludwine Messiaen
Martin McMahon
Ophélia Maertens
Pablo Hollstein
Roderick T Bronson
Scott Granter
P2860
P304
P3181
P356
10.1158/2159-8290.CD-12-0313
P577
2013-03-01T00:00:00Z